MedTrace Logo

Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea

NCT03418610 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-07-24

No results posted yet for this study

Summary

This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.

Conditions

  • Rosacea, Papulopustular

Interventions

DRUG

Azelaic Acid foam 15%

mild to moderate rosacea

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Clinical Research Center of the Carolinas

    lead OTHER

Principal Investigators

  • Todd Schlesinger, MD, FAAD · Medical Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-06
Primary Completion
2019-01-09
Completion
2019-01-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418610 on ClinicalTrials.gov